RVP · XBRL financial data

Retractable Technologies financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RVP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	81,862	188,382	94,819	43,597	33,050	38,266
Cost of goods and services sold	44,854	93,030	66,566	34,489	34,078	38,219
Gross profit	37,008	95,353	28,253	9,108	(1,028)	47
Research and development	575	901	526	581	674	676
General and administrative	8,301	17,378	24,036	14,308	13,555	12,772
Total operating expenses	12,938	22,757	29,106	20,596	20,077	21,222
Operating income (loss)	24,071	72,595	(853)	(11,488)	(21,106)	(21,175)
Interest expense	260	227	171	152	123	88
Income tax expense (benefit)	1,850	18,887	84	(1,905)	8,366	291
Net income (loss)	24,223	56,064	5,079	(7,011)	(11,887)	(12,565)
Earnings per share, basic USD per share	0.80	1.65	0.15	(0.24)	(0.40)	(0.43)
Earnings per share, diluted USD per share	0.80	1.63	0.15	(0.24)	(0.40)	(0.43)
Weighted average shares, basic thousands of shares	33,169	33,871	32,896	29,937	29,937	29,937
Weighted average shares, diluted thousands of shares	33,301	34,245	32,962	29,937	29,937	29,937

Fiscal years (RVP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	17,567	29,163	19,721	12,668	4,235	2,589
Accounts receivable	32,911	34,860	4,835	10,672	7,787	7,904
Inventory	10,235	20,590	20,684	17,581	19,190	17,188
Total current assets	69,478	104,507	88,810	77,650	73,272	63,083
Property and equipment, net	30,817	87,926	100,153	93,479	87,349	79,180
Right-of-use asset	39	—	—	—	—	—
Total assets	104,971	206,305	195,666	179,672	160,724	142,630
Accounts payable	16,256	20,405	6,405	4,779	4,291	5,340
Current portion of long-term debt	1,031	289	286	304	332	—
Total current liabilities	27,902	35,325	12,136	9,377	8,781	9,598
Long-term debt	2,710	1,814	1,533	1,234	900	—
Total liabilities	55,091	107,135	89,129	80,385	73,554	68,255
Retained earnings (accumulated deficit)	(9,668)	41,182	46,029	38,786	26,669	13,873
Total stockholders' equity	49,880	99,169	106,537	99,288	87,171	74,375
Total liabilities and equity	104,971	206,305	195,666	179,672	160,724	142,630
Common shares outstanding (cover page) thousands of shares	33,983	33,123	29,937	29,937	29,937	29,937

Fiscal years (RVP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	24,223	56,064	5,079	(7,011)	(11,887)	(12,565)
Stock-based compensation	—	—	10,126	—	—	—
Depreciation and amortization	832	1,257	4,603	7,527	7,570	7,766
Net cash from operating activities	18,997	32,793	16,768	2,767	(11,557)	(7,064)
Purchases of property and equipment	21,050	58,367	16,830	853	1,440	—
Net cash from investing activities	(19,327)	(63,040)	(31,203)	(10,762)	3,660	5,985
Proceeds from issuing common stock	—	5,300	—	—	—	—
Share repurchases	—	5,271	7,618	—	—	—
Proceeds from long-term debt	1,363	—	—	—	—	—
Repayments of long-term debt	261	275	284	282	305	337
Net cash from financing activities	11,962	41,843	4,993	942	(535)	(567)
Net change in cash	11,632	11,596	(9,442)	(7,054)	(8,432)	(1,647)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Retractable Technologies	2,641	7,201	(1,732)*	29.9M	1.5 quarters	Q2 FY26 10-QJun 30, 2026
Semler Scientific	10,176	7,491	(32,950)*	15.2M	0.3 quarters	Q3 FY25 10-QSep 30, 2025
OSR Health	1,500	316	(2,421)*	35.1M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Sintx Technologies	3,590	452	(2,767)*	6.7M	1.3 quarters	Q2 FY26 10-QJun 30, 2026
Tenon Medical	1,677	1,279	(2,758)*	667,047	0.6 quarters	Q2 FY26 10-QJun 30, 2026
SeaStar Medical Holding	6,959	615	(2,994)*	4.4M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
ENvue Medical	1,084	239	(2,691)*	11.1M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Bone Biologics	6,088	not reported	(532)*	3.4M	9.8 quarters	Q3 FY26 10-QSep 30, 2026
Medinotec	2,584	3,201	108*	11.8M	—	Q2 FY27 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.